Cutting Edge Information

Pharmaceutical companies often opt not to outsource clinical site selection to patient recruitment or site management organizations during Phase 1 clinical testing, according to a new study by ... read more

To aid their patient-focused efforts, many biopharmaceutical companies have turned to outside vendors. According to a study by Cutting Edge Information, drug companies without dedicated patient adherence teams ... read more

New product launches can double a medical affairs team’s financial resources at some biopharmaceutical companies, according to new data published by Cutting Edge Information. Medical affairs teams play ... read more

Better than half of biopharmaceutical companies has a dedicated team in place to unify digital strategies and better navigate the rapidly changing media environment. According to a study ... read more

More than two-thirds of medical science liaison (MSL) team budgets is dedicated to direct salaries and overhead or travel expenses, a recent study from Cutting Edge Information found. ... read more

Drug manufacturers are investing in tightly controlled mHealth pilot programs to better understand where to make future investments, according to a recent study by Cutting Edge Information. ... read more

With all of the activities that new product planning teams often coordinate, the staff size can be construed as relatively low, according to a new study from Cutting ... read more

Many drug companies are ahead of the social media curve. But a closer look reveals that pharmaceutical manufacturers are at widely different stages of implementation, according to a ... read more

A new survey of drug manufacturers found that new product planning teams dedicate upwards of 50% of their time on business development activities. ... read more

A recent Cutting Edge Information report pinpoints efficient communication across functions as pharmaceutical companies’ leading challenge when conducting market research. ... read more

The decision to move investigational drugs to Phase I testing is no longer in the hands of pre-clinical development executives, according to a new study from Cutting Edge ... read more

To accurately respond to incoming inquiries, medical information teams must regularly review their standard response documents. These teams must keep tabs on their companies’ ongoing ... read more

The gap between European and US reimbursement may be narrowing, according to recent analysis by pharmaceutical intelligence firm Cutting Edge Information. ... read more

A majority of surveyed pharmaceutical companies outsource at least part of their regulatory affairs budget. This is up 5% from 2010, demonstrating that fewer ... read more

A majority of surveyed pharmaceutical and biotechnology companies have dedicated medical publications groups in place, according to a report from Cutting Edge Information. ... read more

A new study from Cutting Edge Information discovered that on average, oncology trials reported a total cost of nearly $2 million more than the average total cost of ... read more

Although numerous sites can be beneficial in Phase I clinical trials, new data show that trials with fewer sites encounter fewer enrolling complications, according to a new study ... read more

More than three-quarters (77%) of surveyed pharmaceutical companies have created dedicated portfolio management teams, according to a study by Cutting Edge Information. ... read more

A new study finds that despite budget cuts in pharmaceutical companies as a result of the “Great Recession,” regulatory affairs teams have experienced a consistent increase in their ... read more

The average number of thought leaders working with large pharmaceutical companies declined in one year by 26%, according to a Cutting Edge Information study. ... read more